Prenetics Group Limited (PRE): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRE Stock Price Chart Interactive Chart >
PRE Price/Volume Stats
| Current price | $1.81 | 52-week high | $8.75 |
| Prev. close | $1.85 | 52-week low | $1.24 |
| Day low | $1.77 | Volume | 40,900 |
| Day high | $1.85 | Avg. volume | 69,482 |
| 50-day MA | $3.07 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 79.49M |
Prenetics Group Limited (PRE) Company Bio
Prenetics Group Limited operates as a diagnostics and genetic testing company worldwide. It develops consumer genetic testing and early colorectal cancer screening products; and provides COVID-19 testing, rapid point of care and at-home diagnostic testing, and medical genetic testing products. The company's products include CircleDNA, a consumer genetic testing offering that uses whole exome sequencing; Project Screen, a COVID-19 test; and Circle HealthPod, a molecular testing product for COVID-19. It is also developing ColoClear, a non-invasive stool-based FIT-DNA test for colorectal cancer screening; Circle SnapShot, an at-home blood test with a user-friendly blood sample collection and result delivery system; Circle Medical, a test to identify causal genetic mutations for patients; and Circle One and F1x/Fem, a DNA profile and questionnaire based personalized nutrition solution. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Latest PRE News From Around the Web
Below are the latest news stories about PRENETICS GLOBAL LTD that investors may wish to consider to help them evaluate PRE as an investment opportunity.
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA OutlookPrenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the second quarter ended June 30, 2022. |
The past year for Prenetics Global (NASDAQ:PRE) investors has not been profitableThe simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that... |
Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection DevicePrenetics Global Limited (NASDAQ: PRE), a global leader in genomic and diagnostic testing, announced the launch of Circle Snapshot, a variety of at-home blood tests that feature the world's first painless, patented, push-button blood collection device, to enable individuals to discover one's current health status from home. |
What Kind Of Investors Own Most Of Prenetics Global Limited (NASDAQ:PRE)?If you want to know who really controls Prenetics Global Limited ( NASDAQ:PRE ), then you'll have to look at the makeup... |
Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong KongPrenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test – ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019[1]. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defense against one of |
PRE Price Returns
| 1-mo | -41.99% |
| 3-mo | -52.49% |
| 6-mo | -61.81% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...